HealthInvest Partners AB Trims Stock Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

HealthInvest Partners AB trimmed its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 20.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 120,501 shares of the company’s stock after selling 31,374 shares during the period. Harmony Biosciences makes up 1.9% of HealthInvest Partners AB’s portfolio, making the stock its 18th biggest holding. HealthInvest Partners AB’s holdings in Harmony Biosciences were worth $4,104,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in HRMY. Citigroup Inc. grew its holdings in Harmony Biosciences by 9.8% in the third quarter. Citigroup Inc. now owns 177,843 shares of the company’s stock valued at $7,114,000 after purchasing an additional 15,859 shares during the period. HighTower Advisors LLC boosted its holdings in shares of Harmony Biosciences by 364.0% in the 3rd quarter. HighTower Advisors LLC now owns 79,961 shares of the company’s stock valued at $3,199,000 after purchasing an additional 62,729 shares during the last quarter. Quest Partners LLC grew its stake in shares of Harmony Biosciences by 137.6% during the 3rd quarter. Quest Partners LLC now owns 35,723 shares of the company’s stock valued at $1,429,000 after buying an additional 20,689 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Harmony Biosciences by 68.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock worth $9,217,000 after buying an additional 93,622 shares during the last quarter. Finally, CWA Asset Management Group LLC purchased a new position in shares of Harmony Biosciences in the 3rd quarter worth $576,000. Hedge funds and other institutional investors own 86.23% of the company’s stock.

Insider Buying and Selling at Harmony Biosciences

In other Harmony Biosciences news, CFO Sandip Kapadia sold 25,000 shares of Harmony Biosciences stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $40.18, for a total transaction of $1,004,500.00. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Jeffrey Dierks sold 1,123 shares of the company’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $40.00, for a total value of $44,920.00. The disclosure for this sale can be found here. Insiders sold a total of 72,452 shares of company stock valued at $2,831,679 in the last ninety days. Insiders own 30.80% of the company’s stock.

Harmony Biosciences Trading Down 0.9 %

NASDAQ HRMY opened at $34.56 on Monday. The company’s fifty day simple moving average is $36.57 and its 200-day simple moving average is $35.81. The stock has a market cap of $1.97 billion, a P/E ratio of 16.38, a PEG ratio of 0.47 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a 52 week low of $28.14 and a 52 week high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Cantor Fitzgerald boosted their price target on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a report on Tuesday, February 11th. They set a “buy” rating and a $55.00 target price for the company. Mizuho cut their price target on shares of Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating on the stock in a report on Thursday. HC Wainwright reiterated a “buy” rating and set a $75.00 price objective on shares of Harmony Biosciences in a research note on Wednesday, February 19th. Finally, Needham & Company LLC dropped their price objective on shares of Harmony Biosciences from $52.00 to $50.00 and set a “buy” rating for the company in a research report on Wednesday, February 19th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $53.67.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.